Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Clinical trial NCT07465718 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07465718
- Sponsor
- Orphalan
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2028-02-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.